Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **combination product** containing **delta-9 tetrahydrocannabinol (THC)**—the principal psychoactive cannabinoid of cannabis—and **melatonin**, a hormone regulating the sleep-wake cycle. Together, these agents are primarily formulated for sleep aid purposes, often as edible products (e.g., gummies) intended to initiate and improve sleep. THC exerts its effects mainly through activation of the cannabinoid type 1 receptor in the brain, which can decrease sleep onset latency and enhance melatonin production, thus amplifying sedative effects and sleep quality. Melatonin acts as an agonist at melatonin receptors (MT1, MT2) in the suprachiasmatic nucleus of the hypothalamus, enforcing sleep timing and circadian rhythm regulation. This combination is being investigated for insomnia and sleep disturbances, with preliminary data suggesting additive or synergistic sedative effects[3][5][7][6][2]. Brand manufacturers exist but no widely-recognized single brand name predominates; representative products are available from companies such as Mr. Hemp Flower and Apollo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on delta-9 tetrahydrocannabinol + melatonin.